La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cell Impact Bilan de santé

Santé financière contrôle des critères 3/6

Cell Impact possède un total de capitaux propres de SEK279.9M et une dette totale de SEK21.8M, ce qui porte son ratio d'endettement à 7.8%. Son actif total et son passif total sont SEK345.5M et de SEK65.6M.

Informations clés

7.6%

Ratio d'endettement

SEK 19.73m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 22.62m
Fonds propres	SEK 259.01m
Total du passif	SEK 56.00m
Total des actifs	SEK 315.01m

Mises à jour récentes de la santé financière

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

May 13

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Jan 14

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

May 09

Recent updates

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

May 13

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Jan 14

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

May 09

Investors Who Bought Cell Impact (STO:CI B) Shares Three Years Ago Are Now Up 428%

Feb 21

How Much Is Cell Impact AB (publ) (STO:CI B) Paying Its CEO?

Dec 27

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de CI ( SEK131.8M ) dépassent ses passifs à court terme ( SEK34.4M ).

Passif à long terme: Les actifs à court terme de CI ( SEK131.8M ) dépassent ses passifs à long terme ( SEK31.2M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: CI dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de CI est passé de 2.1% à 7.6% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: CI dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: CI dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 27.4 % chaque année

Cell Impact Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Cell Impact AB (publ) PUBL SHARE AK B to Be Deleted from Other OTC

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

Recent updates

Second quarter 2024 earnings released

Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030

Cell Impact Adds Sealing as A New Part of Production Process

New major risk - Share price stability

First quarter 2024 earnings released: kr0.04 loss per share (vs kr0.40 loss in 1Q 2023)

Cell Impact AB (Publ) Announces Board and Committee Changes

Director recently bought kr91k worth of stock

Full year 2023 earnings released: kr1.11 loss per share (vs kr1.38 loss in FY 2022)

Cell Impact AB (Publ) Appoints Henrik Jackman as Chief Application Engineer

Chief Executive Officer recently bought kr50k worth of stock

Cell Impact AB (publ) Announces CEO Changes

New major risk - Shareholder dilution

Cell Impact AB (Publ) Announces That Stefan Axellie to Leave Role as CFO

Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.38 loss in 3Q 2022)

Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023

New major risk - Market cap size

Cell Impact AB (publ) Announces Anna Frick Will Leave the Board

Chief Executive Officer recently bought kr101k worth of stock

Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028

Cell Impact AB (Publ) Announces Outstanding Measuring Precision Enabling Customers' Product Development

New major risk - Share price stability

Chief Executive Officer recently bought kr50k worth of stock

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

Full year 2022 earnings released: kr1.38 loss per share (vs kr1.35 loss in FY 2021)

Cell Impact AB (publ) to Report Fiscal Year 2023 Results on Mar 24, 2024

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

No independent directors

Third quarter 2022 earnings released: kr0.38 loss per share (vs kr0.25 loss in 3Q 2021)

Second quarter 2022 earnings released

Cell Impact AB (publ) PUBL SHARE AK B to Be Deleted from Other OTC

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings released: kr1.35 loss per share (vs kr0.88 loss in FY 2020)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Cell Impact AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

First quarter 2021 earnings released

Cell Impact AB (publ) Receives SEK 42 Million Order from Plug Power for New Production Line and Flow Plates

Investors Who Bought Cell Impact (STO:CI B) Shares Three Years Ago Are Now Up 428%

Full year 2020 earnings released: kr0.85 loss per share (vs kr1.45 loss in FY 2019)

New 90-day high: kr49.70

Cell Impact Appoints Forrest Zhang as Country Manager in China, Effective May 3, 2021

How Much Is Cell Impact AB (publ) (STO:CI B) Paying Its CEO?

New 90-day high: kr29.30

New 90-day high: kr29.00

Third quarter 2020 earnings released: kr0.12 loss per share

New 90-day low: kr21.35

Cell Impact AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 175 million.

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines